SCHEMBL790579

SCHEMBL790579

Clc1ccc(Cl)c(-c2cc[c]o2)c1

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HPGD P15428 5/20 0.41
HTT P42858 1/20 0.41
TP53 P04637 2/20 0.38
SLC9A1 P19634 3/20 0.38
LMNA P02545 3/20 0.38
HTR2B P41595 1/20 0.38
PDE4D Q08499 1/20 0.38
SMN1; SMN2 Q16637 1/20 0.38
ALDH1A1 P00352 5/20 0.37
MAPT P10636 4/20 0.37
TSHR P16473 3/20 0.37
HSD17B10 Q99714 2/20 0.37
PKM P14618 1/20 0.37
ALOX15 P16050 1/20 0.37
ALOX12 P18054 1/20 0.37
NPSR1 Q6W5P4 3/20 0.36
TDP1 Q9NUW8 3/20 0.36
MAPK1 P28482 1/20 0.36
L3MBTL1 Q9Y468 1/20 0.36
MEN1 O00255 3/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6278390 0.85 AHR (0.42) HPGDHTTTP53LMNASMN1; SMN2
SCHEMBL3386023 0.79 FTO (0.37) HTTSMN1; SMN2ALDH1A1TSHRL3MBTL1
SCHEMBL5462517 0.76 TSHR (0.49) TP53ALDH1A1MAPTTSHRALOX15
SCHEMBL4317762 0.76 CYP2A6 (0.41) HPGDHTTTP53SLC9A1LMNA
SCHEMBL6285196 0.74 ALDH1A1 (0.35) TP53ALDH1A1TSHRHSD17B10CYP3A4
SCHEMBL512928 0.71 NOTUM (0.42) HPGDHTTLMNAALDH1A1MAPT
SCHEMBL4827596 0.71 POLB (0.51) TP53HTR2BPDE4DALDH1A1MAPT
SCHEMBL29364307 0.71 TP53 (0.61) TP53LMNAHTR2BPDE4DALDH1A1
SCHEMBL440944 0.71 TP53 (0.61) TP53LMNAHTR2BPDE4DALDH1A1
SCHEMBL5535370 0.71 AHR (0.50) HPGDHTTTP53SMN1; SMN2ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100016272-A1 HETEROARYLACRYLAMIDES AND THEIR USE AS PHARMACEUTICALS SANOFI-AVENTIS (FR) 2010-01-21 US claimed
EP-2099753-A2 HETEROARYLACRYLAMIDES AND THEIR USE AS PHARMACEUTICALS Sanofi-Aventis (FR) 2009-09-16 EP claimed
WO-2008074413-A2 HETEROARYLACRYLAMIDES AND THEIR USE AS PHARMACEUTICALS FOR THE STIMULATION OF THE EXPRESSION OF ENDOTHELIAL NO SYNTHASE SANOFI-AVENTIS (FR) 2008-06-26 WO claimed
EP-2616459-B1 PYRIDINE COMPOUNDS FOR CONTROLLING INVERTEBRATE PESTS I BASF SE (DE) 2016-05-04 EP disclosed
US-8609700-B2 Pyridine compounds for controlling invertebrate pests I BASF SE (DE) 2013-12-17 US disclosed
EP-2616459-A1 PYRIDINE COMPOUNDS FOR CONTROLLING INVERTEBRATE PESTS I BASF SE (DE) 2013-07-24 EP disclosed
US-20130178502-A1 Pyridine Compounds for Controlling Invertebrate Pests I BASF SE (DE) 2013-07-11 US disclosed
US-8304438-B2 Heteroarylacrylamides and their use as pharmaceuticals SANOFI (FR) 2012-11-06 US disclosed
WO-2012034961-A1 PYRIDINE COMPOUNDS FOR CONTROLLING INVERTEBRATE PESTS I BASF SE (DE) 2012-03-22 WO disclosed
US-20100016272-A1 HETEROARYLACRYLAMIDES AND THEIR USE AS PHARMACEUTICALS SANOFI-AVENTIS (FR) 2010-01-21 US disclosed
EP-2099753-A2 HETEROARYLACRYLAMIDES AND THEIR USE AS PHARMACEUTICALS Sanofi-Aventis (FR) 2009-09-16 EP disclosed
US-20050049245-A1 Heteroaryl-ethanolamine derivatives as antiviral agents PHARMACIA & UPJOHN COMPANY 2005-03-03 US disclosed
US-20040259907-A1 4-OXO-4,7-DIHYDROFURO[2,3-B]PYRIDINE-5-CARBOXAMIDE ANTIVIRAL AGENTS PHARMACIA & UPJOHN COMPANY 2004-12-23 US disclosed
US-6831081-B2 Herpes virus including simplex types 1 and 2, varicella zoster, human cytomegalovirus, Epstein-Barr and human 6, 7 and 8 PHARMACIA & UPJOHN 2004-12-14 US disclosed
WO-2004106345-A2 HETEROARYL-ETHANOLAMINE DERIVATIVES AS ANTIVIRAL AGENTS PHARMACIA & UPJOHN COMPANY (US) 2004-12-09 WO disclosed
US-6825208-B2 SELECTIVE INHIBITORS OF SERINE PROTEASE ENZYMES, ESPECIALLY FACTOR VIIA; MODULATION OF THE COAGULATION CASCADE. BRISTOL-MYERS SQUIBB PHARMA COMPANY 2004-11-30 US disclosed
EP-1465895-A2 4-OXO-4,7-DIHYDROFURO(2,3-B)PYRIDINE-5-CARBOXAMIDE ANTIVIRAL AGENTS PHARMACIA & UPJOHN COMPANY (US) 2004-10-13 EP disclosed
US-20040110786-A1 4-Oxo-4,7-dihydrothieno[2,3-b]pyridine-5-carboxamides as antiviral agents PHARMACIA & UPJOHN COMPANY 2004-06-10 US disclosed
WO-2004022566-A1 4-OXO-4,7-DIHYDROTHIENO[2,3-b]PYRIDINE-5-CARBOXAMIDES AS ANTIVIRAL AGENTS PHARMACIA & UPJOHN COMPANY LLC (US) 2004-03-18 WO disclosed
WO-2003059911-A2 4-OXO-4, 7-DIHYDROFURO[2,3-b]PYRIDINE-5-CARBOXAMIDE ANTIVIRAL AGENTS PHARMACIA & UPJOHN COMPANY (US) 2003-07-24 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040110786-A1 4-Oxo-4,7-dihydrothieno[2,3-b]pyridine-5-carboxamides as antiviral agents ZC3HAV1, ZC3HAV1L, MAVS HPGD 3239/4885HTT 4643/4885TP53 3189/4885
US-20040259907-A1 4-OXO-4,7-DIHYDROFURO[2,3-B]PYRIDINE-5-CARBOXAMIDE ANTIVIRAL AGENTS IL4, ZC3HAV1, IRF3 HPGD 2463/4885HTT 4197/4885TP53 1692/4885
US-20130178502-A1 Pyridine Compounds for Controlling Invertebrate Pests I GRIN2A, PRXL2A, MT-CO2 HPGD 1332/4885HTT 3242/4885TP53 4709/4885
US-20050049245-A1 Heteroaryl-ethanolamine derivatives as antiviral agents RPL35, ZC3HAV1, RPL5 HPGD 3407/4885HTT 3818/4885TP53 3396/4885
US-20100016272-A1 HETEROARYLACRYLAMIDES AND THEIR USE AS PHARMACEUTICALS NOS3, PTGIS, NOS1 HPGD 92/4885HTT 1154/4885TP53 4192/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.